News & Updates
Filter by Specialty:
ART discontinuation tied to toxicity, disease progression in mCRPC patients
Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.
ART discontinuation tied to toxicity, disease progression in mCRPC patients
07 Jun 2024
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
A combination regimen comprising the novel agent GST-HG171 (also known as atilotrelvir) and ritonavir improves clinical symptom recovery and viral clearance in low-risk vaccinated adults with mild-to-moderate COVID-19, findings from a pivotal phase II/III study have shown.
Novel agent plus ritonavir shows favourable signals for mild-to-moderate COVID-19
05 Jun 2024
Tislelizumab improves survival in advanced gastric/gastro-oesophageal junction adenocarcinoma
First-line treatment with tislelizumab plus chemotherapy for advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma yields better overall survival and an acceptable safety profile compared with chemotherapy plus placebo in patients with a programmed death-ligand 1 (PD-L1) tumour area positivity (TAP) score of ≥5 percent, a study has shown.